Evonik: Your Partner in Custom Manufacturing

2:30 - 3:00
Fresh Squeezed Juices Bar for Workshop Attendees

1. Evonik's Strategy and Capabilities
   The strategy of Evonik for serving the pharmaceutical industry will be explained. The asset strategy and the horizontal and vertical integration of the manufacturing sites play a key part in Evonik's flexible approach to pharmaceutical manufacturing. The aim is to produce the best result for the customer in terms of price, quality, and delivery.

   Presenters:

   Robert Koprowski, Ph.D.
   Director Key Accounts, NAFTA
   Evonik Industries

   Klaus Stingl, Ph.D.
   Head of Key Account and Commercial Mgmt, NAFTA/Asia
   Evonik Industries

2. From Inquiry to Delivery: Tools for Project Management, Customer Communication and Work Flow Optimisation
   Excellent customer communication and highly efficient project management are key to success in custom and contract manufacture of today's highly complex pharmaceutical APIs. Evonik will introduce its in-house tools for project management, customer communication and workflow management, with the aid of generic examples of customer projects.

   Presenter:

   Juergen Roos, Ph.D.
   Director, Technology Development
   Evonik Degussa GmbH

3. New Manufacturing Opportunities in the USA – Capabilities in HPAPI production
   With the acquisition of the Tippecanoe Laboratories Site (West Lafayette, IN) from Eli Lilly, Evonik has greatly expanded its production capacity for cGMP manufacture of pharma APIs and advanced intermediates (860 m³ vessel capacity). The new production facilities will be illustrated. A particular feature of the Tippecanoe site is the capability for High Potency API (HPAPI) manufacture at all production scales. The special features and requirements for successful HPAPI manufacture will be presented.

   Presenter:

   Kevin Haehl, P.E.
   Director, Bulk Chemical Manufacturing
   Tippecanoe Laboratories
   Evonik Degussa Corporation

4. Expansion of the Technology Toolbox
   The existing technology capabilities of Evonik Exclusive Synthesis will be presented, together with the areas where the new technologies required for tomorrow's APIs are being developed. An area of emphasis is the synergy between Exclusive Synthesis and other areas of Evonik, which enables Evonik to offer a very wide range of technology opportunities for the customer. These include engineering expertise (continuous processing, micro-reactor technology, process modelling), biotechnology (biocatalysis including enzyme engineering and design and fermentation development), chemical catalysis (tailor-made catalysts optimised for a customer's specific process) and pharma polymers (tailor-made polymers for controlled release drug dosage forms).

   Presenter:

   Ian Grayson, Ph.D.
   Innovation & Techology Manager
   Evonik Degussa GmbH

4:30 - 8:30
Welcome Reception and Dinner